Clinical Trial Update: Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating a monoclonal antibody against PCSK9 to lower LDL-C in patients not currently on lipid-lowering therapy; completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Elevated Low-density Lipoprotein Cholesterol
• Hyperlipidemia

Drugs mentioned

• monoclonal antibody against PCSK9

Snippet

Sponsor: Amgen | Conditions: Hyperlipidemia | Phase 3 | Status: COMPLETED | Results posted: 2015-12-30